Interleukin-2-receptor blockade with daclizumab decreases the incidence of acute rejection in pediatric lung transplant recipients.
Washington University School of Medicine, St. Louis, Mo, USA
S C.
SC
Sweet
M T.
MT
De La Morena
S D.
SD
Shapiro
E N.
EN
Mendeloff
C B.
CB
Huddleston